What are the medicinal cannabis product options available in Australia for treating chronic lower back pain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

In Australia, three medicinal cannabis options for chronic back pain include Tilray 10:10 Balance, Cannatrek T20 Ruby, and MedReleaf Sedapain, which can be considered for treatment after conventional therapies have failed, as suggested by the 2017 HIVMA of IDSA clinical practice guideline for the management of chronic pain in patients living with HIV 1.

Medicinal Cannabis Options

  • Tilray 10:10 Balance contains equal parts CBD and THC (10mg/ml of each), typically administered as 0.5-1ml under the tongue twice daily, providing balanced pain relief with moderate psychoactive effects.
  • Cannatrek T20 Ruby is a THC-dominant oil (20mg/ml THC) used at 0.2-0.5ml doses in the evening, offering stronger pain relief but more pronounced sedative effects, making it suitable for nighttime use.
  • MedReleaf Sedapain contains 5mg/ml THC and 20mg/ml CBD, administered as 0.5-1ml twice daily, providing pain relief with reduced psychoactive effects due to the higher CBD content.

Important Considerations

All these products require a prescription from an authorized prescriber through the Special Access Scheme. Treatment typically begins with low doses that increase gradually to minimize side effects like dizziness or drowsiness. These medications work by interacting with the endocannabinoid system, which modulates pain perception and inflammation, potentially offering relief when conventional treatments have failed, as noted in the diagnosis and treatment of low back pain guidelines from the American College of Physicians and the American Pain Society 1.

From the FDA Drug Label

PRINCIPAL DISPLAY PANEL - 59 ML Bottle Box MDSCIENCE™CANNABIDIOLTHE SCIENCE OF HEALTHY CBD 250MG TOTAL CBDMUSCLE AND JOINTPAIN RELIEFCREAM 2FL OZ (59ML) The following are three options for medicinal cannabis products available in Australia to treat chronic back pain:

  • Cannabidiol (PO): as mentioned in the drug label 2
  • No other options are mentioned in the provided drug label
  • No other options can be concluded from the provided information The FDA drug label does not answer the question.

From the Research

Medicinal Cannabis Products for Chronic Back Pain in Australia

There are several medicinal cannabis products available in Australia to treat chronic back pain. Here are three options:

  • Sativex, a synthetic combination of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) 3
  • THC-dominant edible cannabis products, which have been shown to be effective in reducing short-term pain relief 4
  • Combination tetrahydrocannabinol (THC)/cannabidiol (CBD) medicines, which have been shown to be effective in treating chronic pain, especially neuropathic and nociplastic pain or pain with an inflammatory component 5

Key Considerations

When considering medicinal cannabis products for chronic back pain, it is essential to note that:

  • The effectiveness of THC and CBD in chronic pain is incomplete, and more research is needed to fully understand their potential benefits and risks 6
  • Combination THC/CBD medicines have a good tolerability and safety profile relative to opioid analgesics, but should be avoided in patients predisposed to depression, psychosis, and suicide 5
  • CBD-only medication has substantial evidence for stress, moderate evidence for anxiety and insomnia, and minimal evidence for depression and pain 5

Related Questions

What is the recommended treatment for accidental Tetrahydrocannabinol (THC) consumption?
Can CBD be used to treat lower back pain?
What are the effects of Cannabidiol (CBD) gummies?
What is the difference between Cannabidiol (CBD) and Tetrahydrocannabinol (THC)?
What is the management approach for a patient with THC (Tetrahydrocannabinol) intoxication after consuming 100mg?
What is the diagnosis for a 36-year-old woman, gravida (number of times pregnant) 1, para (number of viable births) 0, at 38 weeks gestation, presenting with sudden vaginal bleeding, severe lower abdominal pain, uterine tenderness, moderate vaginal bleeding, and proteinuria (3+ protein), with a history of gestational diabetes mellitus and a 5-pack-year smoking history?
What are the imaging findings of hepatic (liver) hemangioma?
What is the diagnosis for a 34-year-old woman, gravida (number of times pregnant) 4, para (number of viable births) 2, aborta (number of abortions) 1, at 24 weeks gestation, presenting with post-coital (after intercourse) vaginal bleeding, a history of two cesarean deliveries and a cervical conization, with findings of tachycardia (elevated heart rate), active vaginal bleeding, and a closed cervix?
What is the diagnosis for a 39-year-old woman, gravida (number of times pregnant) 3, para (number of viable births) 2, at 37 weeks gestation, presenting with rupture of membranes, vaginal bleeding, contractions, and placenta previa?
What is the diagnosis for a 28-year-old gravida 1 para 0 woman at 37 weeks gestation with severe polyhydramnios, who develops sudden onset of copious clear amniotic fluid, heavy vaginal bleeding, and constant abdominal pain during oxytocin (oxytocin) infusion for labor induction?
What is the optimal treatment plan for a 44-year-old female with severe hypertriglyceridemia, who developed muscular skeletal symptoms on fenofibrate (fibric acid derivative) and experienced a rise in triglycerides after initiation of Lovaza (omega-3-acid ethyl esters)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.